Posts by Muana Minkoué
US FDA grants Orphan Drug Designation for iOnctura’s Autotaxin cancer therapy
iOnctura’s autotaxin inhibitor cambritaxestat for the treatment of pancreatic cancer gets Orphan Drug Designation (ODD) by the US FDA. IOnctura is a pioneering clinical-stage biotechnology company developing transformative cancer therapies. After assessing its novel chemical and biological properties including an attractive non-clinical safety and efficacy profile, the US Food and Drug Administration (FDA) has…
Read MoreDebiopharm launches expansion of WEE1 inhibitor
Debiopharm aims to further characterise the safety, tolerability, and preliminary anti-tumour activity of its potent WEE1 inhibitor Debio 0123 as monotherapy in three different expansion cohorts. Debiopharm announced the first patient dosed in the expansion of its open-label, non-randomised, multicenter Phase 1 study evaluating Debio 0123, an oral, potent, highly selective and…
Read MoreCollaboration between ABCDx and Andalusian Hospitals
ABCDx is collaborating with Andalusian hospitals to improve stroke triage inside ambulances. Thanks to a public-private grant from the Junta de Andalucía (PIP-0009-2021), the Hospital Universitario Virgen Macarena/IBIS is leading a study to evaluate the potential use of a rapid Point-of-Care device for the direct transfer of stroke patients with a large vessel…
Read MoreSix women-centred initiatives you should know about
From successful entrepreneurs to academics and industry leaders, the Swiss Health Valley is full of inspirational women working in life sciences. As we celebrate Women International’s Day, we’re happy to highlight some of the great initiatives pushing to close the gender gap in life sciences that everybody should keep an eye on. …
Read MoreA multidisciplinary HUG team launches a new study of innovative radioligand therapy (RLT)
A new radioligand to treat glioblastoma and digestive tumors evaluated as a world first at the Geneva University Hospitals (HUG). RLT is a nuclear medicine-based approach that destroys malignant tumors through targeted irradiation. Its specificity lies in the use of a radioactive element embedded in a chemical compound designed to bind specifically to…
Read MoreTerapet receives EUR 1.68 Million Eurostars grant
Terapet announced the receipt of a non-dilutive grant totalling approximately EUR 1.68 Million from the European Commission through the Eurostars Program. Terapet SA, is a Geneva-based CERN spin-off supported by FONGIT, developing an innovative platform technology for imaging in nuclear medicine. The received grant is supported by Innosuisse – the Swiss Innovation Agency,…
Read MoreArtiria Medical, Planny and Algorized receive support from FIT
The three startups have received financial support from the Foundation for technological innovation (FIT). Artiria Medical gets a Tech Growth loan to treat strokes Artiria Medical, a leader in medical device innovation for neurovascular treatments, receives a CHF 500,000 Tech Growth Loan. Their unique deflectable wire technology, which significantly improves the accuracy and speed of…
Read MoreDopamine production is not behind vulnerability to cocaine abuse
A UNIGE team shows that our ability to produce dopamine – the «happiness hormone» – is not correlated with increased vulnerability to drugs. Why do some people who try drugs struggle with substance abuse while others don’t? This question has long puzzled scientists. A team from the University of Geneva (UNIGE) explored the…
Read MoreAgora Care celebrates 10’000 patients and a new collaboration with Caduceo
The Campus biotech startup, recruited over 10’000 patients on its Agora Care platform. This marks an inflection point of the acceleration of Agora Care patient recruitment from early pilot projects to extended recruitment in several large radiology and healthcare networks in Switzerland. Agora Care is developing a patient-centered platform for storage and communication…
Read MoreFONGIT Innovation Fund (FIF) awards funding to Geneva-based tech projects
A seed loan of CHF 100,000 has been granted to previous FIF Grant laureate and HUG spinoff HeroSupport. One grant of CHF 50,000 has been awarded to HUG project SmellRS. The FIF supports innovative technological startups and scale-ups at different stages of their journey with three types of financing options: the FIF Grant…
Read More